Dupilumab — catalyst calendar
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2026-10-07 in 2mo
ESTIMATED |
READOUT
Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥
Phase 3 · Atopic Dermatitis |
REGN REGENERON PHARMACEUTICALS, I | Dupilumab |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|